CTNNB1 and neoplasm: In the β-N model, treatment was ceased at 10 weeks, yet by ~22.5 weeks post-LNP-CTNNB1 treatment, gross tumor burden became equivalent to the tumor burden observed in mice with LNP-CTRL treatment at ~10.5 weeks which had been lethal in β-N mice (Figure S5a–b).